Cephalon To Develop Oncology Franchise Following Acquisition Of CTI’s Trisenox
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon will build a hematology franchise around the Trisenox acquisition; the company may add its Phase II tyrosine kinase inhibitor (CEP-701) and Salmedix’ lymphoma treatment Treanda when that acqusition closes. CTI is selling Trisenox to reinvest in its late-stage pipeline.
You may also be interested in...
Cephalon Files Treanda For Chronic Lymphocytic Leukemia
Submission represents a milestone for Cephalon’s oncology program, firm says.
Cephalon Files Treanda For Chronic Lymphocytic Leukemia
Submission represents a milestone for Cephalon’s oncology program, firm says.
Cephalon To File Treanda For Two Oncology Indications This Year
Company is on track to file chronic lymphocytic leukemia indication in Q3, followed by non-Hodgkin’s lymphoma in Q4.